Skip to main
CVSA

CVSA Stock Forecast & Price Target

CVSA Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Covista is projected to experience strong revenue growth and potentially surpass earnings estimates due to its focus on nursing and healthcare education, along with its partnership with Sallie Mae to address new loan caps. However, potential challenges in recruiting and pricing power could lead to a slowdown in growth if enrollment targets are not met. Despite this risk, the company's focus on operational excellence and goal to reach 65,000 students by FY/29 make it an attractive investment opportunity with an OUTPERFORM rating and a price target of $170, reflecting its potential for premium valuation in the future.

Bears say

Covista is a for-profit educator with a majority of its revenue coming from clinical healthcare education. Despite macro tailwinds in healthcare education, Covista's exposure to the for-profit sector and a history of regulatory challenges raises concerns about future growth potential. Additionally, the company's low composite score could limit its ability to make future acquisitions and its high level of capital return could constrain future investments in campus expansions.

CVSA has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adtalem Global Education Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adtalem Global Education Inc (CVSA) Forecast

Analysts have given CVSA a Buy based on their latest research and market trends.

According to 2 analysts, CVSA has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $150, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $150, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adtalem Global Education Inc (CVSA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.